View Item 

Show simple item record

Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)
dc.contributor.authorScosyrev, Emilen_US
dc.contributor.authorEly, Benjamin W.en_US
dc.contributor.authorMessing, Edward M.en_US
dc.contributor.authorSpeights, V. O.en_US
dc.contributor.authorGrossman, H. Bartonen_US
dc.contributor.authorWood, David P.en_US
dc.contributor.authorde Vere White, Ralph W.en_US
dc.contributor.authorVogelzang, Nicholas J.en_US
dc.contributor.authorTrump, Donald L.en_US
dc.contributor.authorNatale, Ronald B.en_US
dc.contributor.authorTangen, Catherine M.en_US
dc.contributor.authorCrawford, E. Daviden_US
dc.contributor.authorThompson, Ian M.en_US
dc.date.accessioned2011-11-10T15:35:39Z
dc.date.available2012-11-02T18:56:45Zen_US
dc.date.issued2011-09en_US
dc.identifier.citationScosyrev, Emil; Ely, Benjamin W.; Messing, Edward M.; Speights, V.O.; Grossman, H. Barton; Wood, David P.; de Vere White, Ralph W.; Vogelzang, Nicholas J.; Trump, Donald L.; Natale, Ronald B.; Tangen, Catherine M.; Crawford, E. David; Thompson, Ian M. (2011). "Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)." BJU International 108(5). <http://hdl.handle.net/2027.42/86993>en_US
dc.identifier.issn1464-4096en_US
dc.identifier.issn1464-410Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86993
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherUrothelial Carcinomaen_US
dc.subject.otherMixed Histological Featuresen_US
dc.subject.otherNeoadjuvant Chemotherapyen_US
dc.titleDo mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherUniversity of Rochester, Rochester, NYen_US
dc.contributor.affiliationotherSouthwest Oncology Group Statistical Center, Seattle, WAen_US
dc.contributor.affiliationotherScott and White Clinic, Temple, TXen_US
dc.contributor.affiliationotherM.D. Anderson Cancer Center, Houston, TXen_US
dc.contributor.affiliationotherUniversity of California at Davis, Sacramento, CAen_US
dc.contributor.affiliationotherComprehensive Cancer Centers of Nevada, Las Vegas, NV (Southwest Oncology Group and previously, Cancer and Leukemia Group B)en_US
dc.contributor.affiliationotherRoswell Park Cancer Institute, Buffalo, NY (Eastern Cooperative Oncology Group)en_US
dc.contributor.affiliationotherCedars‐Sinai Comprehensive Cancer Center, Los Angeles, CAen_US
dc.contributor.affiliationotherUniversity of Colorado, Aurora, COen_US
dc.contributor.affiliationotherUniversity of Texas Health Science Center, San Antonio, TX, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86993/1/j.1464-410X.2010.09900.x.pdf
dc.identifier.doi10.1111/j.1464-410X.2010.09900.xen_US
dc.identifier.sourceBJU Internationalen_US
dc.identifier.citedreferenceAmerican Cancer Society. Cancer Statistics 2009 Presentation. Available at: http://www.cancer.org/Research/CancerFactsFigures/Cancer‐Statistics‐2009‐presentation. Accessed October 29 2010en_US
dc.identifier.citedreferenceJemal A, Siegel R, Ward E et al. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225 – 49en_US
dc.identifier.citedreferenceStenzl A, Cowan NC, De Santis M et al. Guidelines on Bladder Cancer: Muscle‐Invasive and Metastatic. Arnheim, the Netherlands: European Association of Urology, 2008: 56en_US
dc.identifier.citedreferenceStein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1,054 patients. J Clin Oncol 2001; 19: 666 – 75en_US
dc.identifier.citedreferenceAdvanced Bladder Cancer (ABC) Meta‐Analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta‐analysis of individual patient data. Eur Urol 2005; 48: 202 – 5en_US
dc.identifier.citedreferenceGrossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859 – 66en_US
dc.identifier.citedreferenceInternational Collaboration of Triallists on Behalf of the Medical Research Council Advanced Bladder Cancer Working Party. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle‐invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354: 533 – 40en_US
dc.identifier.citedreferenceWasco M, Daignault Y, Zhang L et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007; 70: 69 – 74en_US
dc.identifier.citedreferenceLogothetis CJ, Dexeus FH, Chong C et al. Cisplatin, cyclophosphomide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol 1989; 141: 33 – 7en_US
dc.identifier.citedreferenceKastritis E, Dimopoulos N, Antoniou C et al. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum‐based chemotherapy. Anticancer Res 2006; 26: 3865 – 9en_US
dc.identifier.citedreferenceBeahrs OH, Henson DE, Hutter RVP eds. Manual for Staging of Cancer, 4th edn. Philadelphia: Lippincott, 1992: 195 – 200en_US
dc.identifier.citedreferenceRothman K, Greenland S, Lash T. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008: 266en_US
dc.identifier.citedreferenceSzklo M, Nieto F. Epidemiology – Beyond the Basics, 2nd edn. Sudbury, MA: Jones and Bartlet, 2007: 422en_US
dc.identifier.citedreferenceWoodward M. Epidemiology – Study Design and Data Analysis. Boca Raton, FL: CRC Press, 2005: 184 – 5, 207en_US
dc.identifier.citedreferenceCox D. Regression models and life tables. J Royal Stat Soc 1972; B34: 187en_US
dc.identifier.citedreferenceGore JL, Lai J, Setodji CM et al. Mortality increases when radical cystectomy is delayed more than 12 weeks. Cancer 2009; 115: 988 – 96en_US
dc.identifier.citedreferenceBlack PC, Brown GA, Colin PN et al. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2009; 27: 3 – 7en_US
dc.identifier.citedreferenceVon der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068 – 77en_US
dc.identifier.citedreferenceGreenland S. Tests for interaction in epidemiologic studies: a review and a study of power. Stat Med 1983; 2: 243 – 51en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1464-410X.2010.09900.x.pdf
Size:
311.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.